GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumosa Therapeutics Co Ltd (ROCO:6535) » Definitions » Shiller PE Ratio

Lumosa Therapeutics Co (ROCO:6535) Shiller PE Ratio : (As of Sep. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lumosa Therapeutics Co Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lumosa Therapeutics Co Shiller PE Ratio Historical Data

The historical data trend for Lumosa Therapeutics Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumosa Therapeutics Co Shiller PE Ratio Chart

Lumosa Therapeutics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lumosa Therapeutics Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lumosa Therapeutics Co's Shiller PE Ratio

For the Biotechnology subindustry, Lumosa Therapeutics Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumosa Therapeutics Co's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lumosa Therapeutics Co's Shiller PE Ratio falls into.



Lumosa Therapeutics Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Lumosa Therapeutics Co's E10 for the quarter that ended in Jun. 2024 is calculated as:

For example, Lumosa Therapeutics Co's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0.409/132.5538*132.5538
=0.409

Current CPI (Jun. 2024) = 132.5538.

Lumosa Therapeutics Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.388 100.560 -0.511
201412 0.000 99.070 0.000
201503 -0.497 99.621 -0.661
201506 -0.705 100.684 -0.928
201509 -1.192 100.392 -1.574
201512 -0.388 99.792 -0.515
201603 -0.626 100.470 -0.826
201606 -0.517 101.688 -0.674
201609 -0.864 101.861 -1.124
201612 -0.616 101.863 -0.802
201703 -0.487 102.862 -0.628
201706 -0.715 103.349 -0.917
201709 -0.527 104.136 -0.671
201712 -0.487 104.011 -0.621
201803 -0.179 105.290 -0.225
201806 -0.328 106.317 -0.409
201809 -0.139 106.507 -0.173
201812 0.129 105.998 0.161
201903 -0.686 107.251 -0.848
201906 0.119 108.070 0.146
201909 -0.666 108.329 -0.815
201912 -0.805 108.420 -0.984
202003 -0.944 108.902 -1.149
202006 -0.666 108.767 -0.812
202009 -0.397 109.815 -0.479
202012 -0.657 109.897 -0.792
202103 0.459 111.754 0.544
202106 -0.738 114.631 -0.853
202109 3.093 115.734 3.543
202112 -2.185 117.630 -2.462
202203 -1.137 121.301 -1.242
202206 -1.197 125.017 -1.269
202209 -0.948 125.227 -1.003
202212 0.239 125.222 0.253
202303 0.888 127.348 0.924
202306 -0.918 128.729 -0.945
202309 -0.738 129.860 -0.753
202312 -0.698 129.419 -0.715
202403 -0.708 131.776 -0.712
202406 0.409 132.554 0.409

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lumosa Therapeutics Co  (ROCO:6535) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Lumosa Therapeutics Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Lumosa Therapeutics Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumosa Therapeutics Co Business Description

Traded in Other Exchanges
N/A
Address
Yuanyuan Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
LUMOSA THERAPEUTICS CO LTD develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of CNS, oncology, and inflammatory diseases. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan and America. Its product portfolio includes LT - 1001 and LT - 3001 for Analgesic Injection and Novel Small Molecules for the Treatment of Acute Ischemic Stroke.

Lumosa Therapeutics Co Headlines

No Headlines